Karin J Neufeld1, Jeannie-Marie S Leoutsakos2, Haijuan Yan3, Shihong Lin3, Jeffrey S Zabinski3, Victor D Dinglas4, Megan M Hosey5, Ann M Parker4, Ramona O Hopkins6, Dale M Needham7. 1. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD; Outcomes After Critical Illness and Surgery (OACIS) Group, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: kneufel2@jh.edu. 2. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD; Outcomes After Critical Illness and Surgery (OACIS) Group, Johns Hopkins University School of Medicine, Baltimore, MD. 3. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD. 4. Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; Outcomes After Critical Illness and Surgery (OACIS) Group, Johns Hopkins University School of Medicine, Baltimore, MD. 5. Department of Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, MD; Outcomes After Critical Illness and Surgery (OACIS) Group, Johns Hopkins University School of Medicine, Baltimore, MD. 6. Neuroscience Center and Psychology Department, Brigham Young University, Provo, UT; Pulmonary and Critical Care Medicine, Intermountain Healthcare, and Center for Humanizing Critical Care, Intermountain Medical Center, Murray, UT. 7. Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Physical Medicine and Rehabilitation, Johns Hopkins University School of Medicine, Baltimore, MD; Outcomes After Critical Illness and Surgery (OACIS) Group, Johns Hopkins University School of Medicine, Baltimore, MD.
Abstract
BACKGROUND: Fatigue is commonly reported by ARDS survivors, but empirical data are scarce. RESEARCH QUESTION: This study evaluated fatigue prevalence and associated variables in a prospective study of ARDS survivors. STUDY DESIGN AND METHODS: This analysis is part of the ARDSNet Long-Term Outcomes Study (ALTOS) conducted at 38 US hospitals. Using age- and sex-adjusted, time-averaged random effects regression models, we evaluated associations between the validated Functional Assessment of Chronic Illness Therapy-Fatigue Scale with patient and critical illness variables, and with physical, cognitive, and mental health status at 6 and 12 months following ARDS. RESULTS: Among ARDS survivors, 501 of 711 (70%) and 436 of 659 (66%) reported clinically significant symptoms of fatigue at 6 and 12 months, respectively, with 41% and 28% reporting clinically important improvement and worsening (n = 638). At 6 months, the prevalence of fatigue (70%) was greater than that of impaired physical functioning (50%), anxiety (42%), and depression (36%); 46% reported both impaired physical function and fatigue, and 27% reported co-existing anxiety, depression, and fatigue. Fatigue was less severe in men and in those employed prior to ARDS. Critical illness variables (eg, illness severity, length of stay) had little association with fatigue symptoms. Worse physical, cognitive, and mental health symptoms were associated with greater fatigue at both the 6- and 12-month follow-up. INTERPRETATION: During the first year following ARDS, more than two-thirds of survivors reported clinically significant fatigue symptoms. Due to frequent co-occurrence, clinicians should evaluate and manage survivors' physical, cognitive, and mental health status when fatigue is endorsed.
BACKGROUND:Fatigue is commonly reported by ARDS survivors, but empirical data are scarce. RESEARCH QUESTION: This study evaluated fatigue prevalence and associated variables in a prospective study of ARDS survivors. STUDY DESIGN AND METHODS: This analysis is part of the ARDSNet Long-Term Outcomes Study (ALTOS) conducted at 38 US hospitals. Using age- and sex-adjusted, time-averaged random effects regression models, we evaluated associations between the validated Functional Assessment of Chronic Illness Therapy-Fatigue Scale with patient and critical illness variables, and with physical, cognitive, and mental health status at 6 and 12 months following ARDS. RESULTS: Among ARDS survivors, 501 of 711 (70%) and 436 of 659 (66%) reported clinically significant symptoms of fatigue at 6 and 12 months, respectively, with 41% and 28% reporting clinically important improvement and worsening (n = 638). At 6 months, the prevalence of fatigue (70%) was greater than that of impaired physical functioning (50%), anxiety (42%), and depression (36%); 46% reported both impaired physical function and fatigue, and 27% reported co-existing anxiety, depression, and fatigue. Fatigue was less severe in men and in those employed prior to ARDS. Critical illness variables (eg, illness severity, length of stay) had little association with fatigue symptoms. Worse physical, cognitive, and mental health symptoms were associated with greater fatigue at both the 6- and 12-month follow-up. INTERPRETATION: During the first year following ARDS, more than two-thirds of survivors reported clinically significant fatigue symptoms. Due to frequent co-occurrence, clinicians should evaluate and manage survivors' physical, cognitive, and mental health status when fatigue is endorsed.
Authors: Todd W Rice; Arthur P Wheeler; B Taylor Thompson; Jay Steingrub; R Duncan Hite; Marc Moss; Alan Morris; Ning Dong; Peter Rock Journal: JAMA Date: 2012-02-05 Impact factor: 56.272
Authors: Kitty S Chan; Lisa Aronson Friedman; O Joseph Bienvenu; Victor D Dinglas; Brian H Cuthbertson; Richard Porter; Christina Jones; Ramona O Hopkins; Dale M Needham Journal: Gen Hosp Psychiatry Date: 2016-07-12 Impact factor: 3.238
Authors: Todd W Rice; Arthur P Wheeler; B Taylor Thompson; Bennett P deBoisblanc; Jay Steingrub; Peter Rock Journal: JAMA Date: 2011-10-05 Impact factor: 56.272
Authors: Margaret S Herridge; Marc Moss; Catherine L Hough; Ramona O Hopkins; Todd W Rice; O Joseph Bienvenu; Elie Azoulay Journal: Intensive Care Med Date: 2016-03-30 Impact factor: 17.440
Authors: Jonathon D Truwit; Gordon R Bernard; Jay Steingrub; Michael A Matthay; Kathleen D Liu; Timothy E Albertson; Roy G Brower; Carl Shanholtz; Peter Rock; Ivor S Douglas; Bennett P deBoisblanc; Catherine L Hough; R Duncan Hite; B Taylor Thompson Journal: N Engl J Med Date: 2014-05-18 Impact factor: 91.245
Authors: Yvonne M J Goërtz; Martijn A Spruit; Alex J Van 't Hul; Jeannette B Peters; Maarten Van Herck; Nienke Nakken; Remco S Djamin; Chris Burtin; Melissa S Y Thong; Arnold Coors; Yvonne Meertens-Kerris; Emiel F M Wouters; Judith B Prins; Frits M E Franssen; Jean W M Muris; Lowie E G W Vanfleteren; Mirjam A G Sprangers; Daisy J A Janssen; Jan H Vercoulen Journal: Ther Adv Respir Dis Date: 2019 Jan-Dec Impact factor: 4.031
Authors: Karissa Weidman; Elyse LaFond; Katherine L Hoffman; Parag Goyal; Christopher N Parkhurst; Heather Derry-Vick; Edward Schenck; Lindsay Lief Journal: Ann Am Thorac Soc Date: 2022-07
Authors: Borja Sañudo; Adérito Seixas; Rainer Gloeckl; Jörn Rittweger; Rainer Rawer; Redha Taiar; Eddy A van der Zee; Marieke J G van Heuvelen; Ana Cristina Lacerda; Alessandro Sartorio; Michael Bemben; Darryl Cochrane; Trentham Furness; Danúbia de Sá-Caputo; Mario Bernardo-Filho Journal: Int J Environ Res Public Health Date: 2020-05-22 Impact factor: 3.390
Authors: Shannon M Fernando; Danial Qureshi; Manish M Sood; Michael Pugliese; Robert Talarico; Daniel T Myran; Margaret S Herridge; Dale M Needham; Bram Rochwerg; Deborah J Cook; Hannah Wunsch; Robert A Fowler; Damon C Scales; O Joseph Bienvenu; Kathryn M Rowan; Magdalena Kisilewicz; Laura H Thompson; Peter Tanuseputro; Kwadwo Kyeremanteng Journal: BMJ Date: 2021-05-05
Authors: Han Su; Hilaire J Thompson; Susanne May; Victor D Dinglas; Catherine L Hough; Megan M Hosey; Ramona O Hopkins; Biren B Kamdar; Dale M Needham Journal: Chest Date: 2021-03-14 Impact factor: 10.262
Authors: Frederikus A Klok; Gudula J A M Boon; Stefano Barco; Matthias Endres; J J Miranda Geelhoed; Samuel Knauss; Spencer A Rezek; Martijn A Spruit; Jörg Vehreschild; Bob Siegerink Journal: Eur Respir J Date: 2020-07-02 Impact factor: 16.671